Udo Hoffmann1, Tomas G Neilan1,2, Zsofia D Drobni1,3, Raza M Alvi1, Jana Taron1,4, Amna Zafar1, Sean P Murphy5, Paula K Rambarat5, Rayma C Mosarla5, Charlotte Lee5, Daniel A Zlotoff2, Vineet K Raghu1, Sarah E Hartmann1, Hannah K Gilman1, Jingyi Gong1, Leyre Zubiri6, Ryan J Sullivan6, Kerry L Reynolds6, Thomas Mayrhofer1,7, Lili Zhang8. 1. Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology (Z.D.D., R.M.A., J.T., A.Z., V.K.R., S.E.H., H.K.G., J.G., T.M., U.H., T.G.N.), Massachusetts General Hospital, Harvard Medical School, Boston. 2. Division of Cardiology (D.A.Z., T.G.N.), Massachusetts General Hospital, Harvard Medical School, Boston. 3. Cardiovascular Imaging Research Group, Heart and Vascular Center, Semmelweis University, Budapest, Hungary (Z.D.D.). 4. Department of Radiology, University Hospital Freiburg, Freiburg, Germany (J.T.). 5. Division of Internal Medicine (S.P.M., P.K.R., R.C.M., C.L.), Massachusetts General Hospital, Harvard Medical School, Boston. 6. Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., K.L.R.), Massachusetts General Hospital, Harvard Medical School, Boston. 7. School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany (T.M.). 8. Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (L. Zhang).
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events. METHODS: The study was situated in a single academic medical center. The primary analysis evaluated whether exposure to an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls matched by age, a history of cardiovascular events, and cancer type. In a second design, a case-crossover analysis was performed with an at-risk period defined as the 2-year period after and the control period as the 2-year period before treatment. The primary outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary revascularization, and ischemic stroke). Secondary outcomes included the individual components of the primary outcome. In addition, in an imaging substudy (n=40), the rate of atherosclerotic plaque progression was compared from before to after the ICI was started. All study measures and outcomes were blindly adjudicated. RESULTS: In the matched cohort study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard ratio, 3.3 [95% CI, 2.0-5.5]; P<0.001). There was a similar increase in each of the individual components of the primary outcome. In the case-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95% CI, 3.5-6.5]; P<0.001). In the imaging study, the rate of progression of total aortic plaque volume was >3-fold higher with ICIs (from 2.1%/y before 6.7%/y after). This association between ICI use and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids. CONCLUSIONS: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk before, during, and after treatment should be considered among patients on an ICI.
BACKGROUND: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events. METHODS: The study was situated in a single academic medical center. The primary analysis evaluated whether exposure to an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls matched by age, a history of cardiovascular events, and cancer type. In a second design, a case-crossover analysis was performed with an at-risk period defined as the 2-year period after and the control period as the 2-year period before treatment. The primary outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary revascularization, and ischemic stroke). Secondary outcomes included the individual components of the primary outcome. In addition, in an imaging substudy (n=40), the rate of atherosclerotic plaque progression was compared from before to after the ICI was started. All study measures and outcomes were blindly adjudicated. RESULTS: In the matched cohort study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard ratio, 3.3 [95% CI, 2.0-5.5]; P<0.001). There was a similar increase in each of the individual components of the primary outcome. In the case-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95% CI, 3.5-6.5]; P<0.001). In the imaging study, the rate of progression of total aortic plaque volume was >3-fold higher with ICIs (from 2.1%/y before 6.7%/y after). This association between ICI use and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids. CONCLUSIONS: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk before, during, and after treatment should be considered among patients on an ICI.
Authors: Jeffrey C Kwong; Kevin L Schwartz; Michael A Campitelli; Hannah Chung; Natasha S Crowcroft; Timothy Karnauchow; Kevin Katz; Dennis T Ko; Allison J McGeer; Dayre McNally; David C Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; George Zahariadis; Jonathan B Gubbay Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245
Authors: Jamal S Rana; Grace H Tabada; Matthew D Solomon; Joan C Lo; Marc G Jaffe; Sue Hee Sung; Christie M Ballantyne; Alan S Go Journal: J Am Coll Cardiol Date: 2016-05-10 Impact factor: 24.094
Authors: Janet Lo; Michael T Lu; Ezinne J Ihenachor; Jeffrey Wei; Sara E Looby; Kathleen V Fitch; Jinhee Oh; Chloe O Zimmerman; Janice Hwang; Suhny Abbara; Jorge Plutzky; Gregory Robbins; Ahmed Tawakol; Udo Hoffmann; Steven K Grinspoon Journal: Lancet HIV Date: 2015-01-09 Impact factor: 12.767
Authors: Stephen J Nicholls; Christie M Ballantyne; Philip J Barter; M John Chapman; Raimund M Erbel; Peter Libby; Joel S Raichlen; Kiyoko Uno; Marilyn Borgman; Kathy Wolski; Steven E Nissen Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245
Authors: Liam Smeeth; Sara L Thomas; Andrew J Hall; Richard Hubbard; Paddy Farrington; Patrick Vallance Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: Dawn M Fernandez; Adeeb H Rahman; Nicolas F Fernandez; Aleksey Chudnovskiy; El-Ad David Amir; Letizia Amadori; Nayaab S Khan; Christine K Wong; Roza Shamailova; Christopher A Hill; Zichen Wang; Romain Remark; Jennifer R Li; Christian Pina; Christopher Faries; Ahmed J Awad; Noah Moss; Johan L M Bjorkegren; Seunghee Kim-Schulze; Sacha Gnjatic; Avi Ma'ayan; J Mocco; Peter Faries; Miriam Merad; Chiara Giannarelli Journal: Nat Med Date: 2019-10-07 Impact factor: 53.440
Authors: Laura Strauss; Mohamed A A Mahmoud; Jessica D Weaver; Natalia M Tijaro-Ovalle; Anthos Christofides; Qi Wang; Rinku Pal; Min Yuan; John Asara; Nikolaos Patsoukis; Vassiliki A Boussiotis Journal: Sci Immunol Date: 2020-01-03
Authors: Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang Journal: J Am Coll Cardiol Date: 2022-02-15 Impact factor: 24.094
Authors: Kalyan R Chitturi; Ethan A Burns; Ibrahim N Muhsen; Kartik Anand; Barry H Trachtenberg Journal: Curr Oncol Rep Date: 2022-02-22 Impact factor: 5.075
Authors: Virginia S Hahn; Kathleen W Zhang; Lova Sun; Vivek Narayan; Daniel J Lenihan; Bonnie Ky Journal: Circ Res Date: 2021-05-13 Impact factor: 17.367
Authors: Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Jingyi Gong; Zsofia Dora Drobni; Amna Zafar; Thiago Quinaglia; Sarah Hartmann; Hannah K Gilman; Vineet K Raghu; Carlos Gongora; Meghan E Sise; Raza M Alvi; Leyre Zubiri; Anju Nohria; Ryan Sullivan; Kerry L Reynolds; Daniel Zlotoff; Tomas G Neilan Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751